Swiss dental medtech company vVardis Holding AG has secured a significant strategic investment from funds managed by Apollo. Announced on April 27, 2026, this partnership is set to accelerate the global expansion of vVardis's revolutionary Curodont™ technology. The funding solidifies the company's position as a leading European healthcare unicorn dedicated to transforming dental care with non-invasive solutions for treating tooth decay.
Revolutionizing Cavity Treatment
vVardis is redefining the approach to dental cavities with its Curodont™ platform, the first commercially available peptide-based formulation for non-invasive treatment. This innovative technology supports natural enamel repair by facilitating the formation of new mineral crystal structures throughout the affected tooth area. It offers dental professionals a simple, drill-free alternative for managing early-stage decay, shifting the paradigm from restoration to regeneration.
The market has responded with remarkable speed to this new treatment option, reflecting a significant unmet need in the dental industry. Since its U.S. launch over two years ago, Curodont™ Repair Fluoride Plus has been used to treat approximately three million teeth. The technology is now utilized in nearly 20% of general dentistry practices across the nation, demonstrating its rapid and widespread adoption.
A Partnership Fueled by Innovation
Apollo's investment underscores its confidence in vVardis's unique market position and scientifically validated approach. Jeremy Honeth, a partner at Apollo, noted that vVardis has pioneered a new category in dental care backed by peer-reviewed clinical studies. The investment is intended to support the company's continued expansion, bringing this advanced restorative therapy to more practices and patients worldwide.
The founders, Drs. Haley and Goly Abivardi, view the partnership as a crucial step in their mission to advance dental science. Dr. Haley Abivardi emphasized that Curodont™ fills a long-standing gap for a non-invasive treatment when prevention fails. Dr. Goly Abivardi added that the investment reinforces their leadership in generative dentistry and supports a future where oral science is more medically driven.
Global Expansion and Industry Impact
With the new capital, vVardis plans to aggressively scale its commercial operations across key international markets. The primary focus will be on strengthening its commercial foundation in the United States and Europe, ensuring broader access to its technology. This strategic expansion aims to make Curodont™ a new standard of care for early caries treatment on a global scale.
The timing of this innovation is critical, as tooth decay remains the most prevalent non-communicable disease globally, affecting nearly 90% of adults in the U.S. alone. Untreated cavities can contribute to serious chronic health issues, highlighting the connection between oral and overall health. vVardis's technology offers a proactive and less invasive solution to this widespread public health challenge.
This strategic investment from Apollo marks a pivotal moment for vVardis and the broader dental industry. It not only validates the company's pioneering work in non-invasive treatments but also provides the resources to make this technology a global standard. As vVardis expands its reach, Curodont™ is poised to fundamentally change how dental professionals and patients approach the management of tooth decay.